BIM
OMED

Bogle Investment Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Bogle Investment Management’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-111,937
Closed -$1.13M – 552
2016
Q1 		$1.13M Buy
+111,937
New +$1.31M 0.08% 253

Other funds holding OMED

ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bogle Investment Management's OMED Position: Q2 2016 in Review

Bogle Investment Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2016, closing a stake of 111,937 shares — an estimated $1.13M sold.

Bogle Investment Management first reported a position in OMED in Q1 2016 and held it in 1 quarter. The position peaked at $1.13M in Q1 2016. 84 funds tracked by Wall St. Rank hold OMED as of Q2 2016.

  • Bogle Investment Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Bogle Investment Management sold 111,937 OncoMed Pharmaceuticals, Inc. shares in Q2 2016, an estimated $1.13M.
  • Bogle Investment Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2016 and held it in 1 quarter.
  • Bogle Investment Management's OncoMed Pharmaceuticals, Inc. position peaked at $1.13M in Q1 2016.
  • 84 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2016.

Based on Bogle Investment Management's 13F filing for Q2 2016, filed 12 Aug 2016.